--- title: "Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway" type: "News" locale: "en" url: "https://longbridge.com/en/news/284380019.md" description: "Rocket Pharmaceuticals (RCKT) has sold a Rare Pediatric Disease Priority Review Voucher for $180 million, extending its cash runway into Q2 2028. This non-dilutive capital will support its cardiovascular gene therapy programs, including candidates for Danon disease and other cardiomyopathies. Despite a recent Buy rating with a $12.00 price target, analysts express concerns over the company's weak financial performance and ongoing cash burn. Rocket focuses on gene therapies for rare cardiovascular diseases and is listed on Nasdaq." datetime: "2026-04-28T11:58:21.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/284380019.md) - [en](https://longbridge.com/en/news/284380019.md) - [zh-HK](https://longbridge.com/zh-HK/news/284380019.md) --- # Rocket Pharmaceuticals Monetizes Voucher to Extend Cash Runway ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks The latest announcement is out from Rocket Pharmaceuticals ( (RCKT) ). On April 26, 2026, Rocket Pharmaceuticals entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher that it was awarded after the U.S. Food and Drug Administration granted accelerated approval to its gene therapy KRESLADI for severe leukocyte adhesion deficiency-I in pediatric patients. The buyer will pay $180 million in cash for the voucher, with closing subject to customary conditions including clearance under U.S. antitrust review rules. Rocket said on April 28, 2026 that monetizing the voucher provides $180 million of non-dilutive capital, extending its cash runway into the second quarter of 2028 and reinforcing its strategy of prioritizing cardiovascular gene therapy programs. The proceeds are earmarked to advance clinical-stage candidates for Danon disease, PKP2-associated arrhythmogenic cardiomyopathy and BAG3-associated dilated cardiomyopathy, strengthening the company’s funding profile as competition intensifies in genetic therapies for rare cardiac disorders. The most recent analyst rating on (RCKT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page. **Spark’s Take on RCKT Stock** According to Spark, TipRanks’ AI Analyst, RCKT is a Neutral. The score is held down primarily by weak financial performance (no revenue, persistent losses, and ongoing cash burn). Technicals are only mildly supportive, while valuation is constrained by negative earnings and no dividend. Offsetting these, the FDA accelerated approval and Priority Review Voucher are meaningful positives that improve the outlook and financial flexibility. To see Spark’s full report on RCKT stock, click here. **More about Rocket Pharmaceuticals** Rocket Pharmaceuticals, Inc. is a fully integrated, commercial-stage biotechnology company focused on gene therapies for rare and devastating cardiovascular diseases, with additional programs in hematology and immunology. Its cardiovascular pipeline includes three clinical-stage programs targeting hypertrophic, arrhythmogenic and dilated inherited cardiomyopathies, addressing more than 100,000 patients in the U.S. and EU. The company leverages proprietary AAV manufacturing capabilities and multi-year efficacy and safety data in cardiac gene therapy, and it has experience treating cardiac patients in late-stage AAV programs. Rocket is listed on Nasdaq under the ticker RCKT and operates out of Cranbury, New Jersey. **Average Trading Volume:** 3,289,814 **Technical Sentiment Signal:** Sell **Current Market Cap:** $384.1M See more data about RCKT stock on TipRanks’ Stock Analysis page. ### Related Stocks - [RCKT.US](https://longbridge.com/en/quote/RCKT.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [RCKTW.US](https://longbridge.com/en/quote/RCKTW.US.md) ## Related News & Research - [REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval](https://longbridge.com/en/news/286443456.md) - [](https://longbridge.com/en/news/286807703.md) - [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md) - [Editas Showcases Promising EDIT-401 Hyperlipidemia Preclinical Data](https://longbridge.com/en/news/286407513.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)